Keyphrases
Rapamycin
100%
Insulin Receptor Substrate 1 (IRS1)
100%
Vanadate
100%
Glucose-stimulated Insulin Secretion
100%
Insulin
66%
Phosphoinositide 3-kinase (PI3K)
41%
Glucose Uptake
41%
Tyrosine Phosphorylation
33%
L6 Skeletal muscle Cells
33%
Kinase Activity
25%
Proteasomal Degradation
25%
Sodium Orthovanadate
25%
Fold Increase
16%
Mass Loss
16%
MTOR Inhibitor
16%
Vanadium
8%
Mammalian Target of Rapamycin (mTOR)
8%
4-fold
8%
Protein Tyrosine Phosphatase 1B (PTP1B)
8%
Diabetes
8%
Protease Inhibitors
8%
Synergize
8%
Negative Regulation
8%
Glucose Transport
8%
Vanadyl Sulfate
8%
MG132
8%
Serine Phosphorylation
8%
Insulin Action
8%
Subtherapeutic
8%
Dual Inhibition
8%
Biochemistry, Genetics and Molecular Biology
Insulin Receptor
100%
Glucose Transport
100%
Phosphoinositide 3-Kinase
41%
Skeletal Muscle
33%
Mechanistic Target of Rapamycin
25%
Tyrosine
16%
Tyrosine Phosphorylation
16%
Dephosphorylation
16%
Serine
8%
Sulfate
8%
Protein Tyrosine Phosphatase
8%
Proteasome Inhibitor
8%
Sodium Orthovanadate
8%
Neuroscience
Glucose Transport
100%
Insulin Receptor
100%
Phosphoinositide 3-Kinase
41%
Skeletal Muscle
33%
Mammalian Target of Rapamycin
25%
Protein Phosphorylation
16%
Dephosphorylation
16%
Serine
8%
Protein Tyrosine Phosphatase
8%
Proteasome Inhibitor
8%
Pharmacology, Toxicology and Pharmaceutical Science
Rapamycin
100%
Insulin Receptor Substrate 1
100%
Phosphatidylinositol 3 Kinase
45%
Mammalian Target of Rapamycin Inhibitor
18%
Mammalian Target of Rapamycin
9%
Protein Tyrosine Phosphatase
9%
Serine
9%
Insulin Receptor Substrate
9%
Sodium Orthovanadate
9%
Proteasome Inhibitor
9%
Vanadyl Sulfate
9%